



## **ALX Oncology Announces November 2020 Virtual Investor Conference Participation**

November 2, 2020

BURLINGAME, Calif., Nov. 02, 2020 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., ("ALX Oncology") (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two virtual investor conferences in November.

### **29<sup>th</sup> Annual Credit Suisse Virtual Healthcare Conference**

Format: Fireside chat with covering analyst, Martin Auster, M.D.

Date: Monday, November 9

Time: 11:45 AM Eastern Time

Webcast link: Available [here](#)

### **Jefferies Virtual London Healthcare Conference**

Format: Fireside chat with covering analyst, Michael Yee

Date: Thursday, November 19

Time: 1:10 PM Eastern Time

Webcast link: Available [here](#)

A live webcast of the fireside chats can be accessed by visiting the Investors section of ALX Oncology's website at [www.alxoncology.com](http://www.alxoncology.com) and selecting the [Investor Calendar](#) under the News and Events tab. A replay of the webcasts will be archived for up to 90 days following the presentation dates.

### **About ALX Oncology**

ALX Oncology is a publicly traded, clinical-stage immuno-oncology company focused on helping patients fight cancer by developing therapies that block the CD47 checkpoint pathway and bridge the innate and adaptive immune system. ALX Oncology's lead product candidate, ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents. ALX Oncology intends to continue clinical development of ALX148 for the treatment of a range of solid tumor indications and myelodysplastic syndromes. For more information, please visit ALX Oncology's website at <https://www.alxoncology.com>.

Investor Contact: Peter Garcia Chief Financial Officer, ALX Oncology (650) 466-7125 Ext. 113 [peter@alxoncology.com](mailto:peter@alxoncology.com) Argot Partners (212)-600-1902 [alxoncology@argotpartners.com](mailto:alxoncology@argotpartners.com) Media Contact: Karen Sharma MacDougall (781) 235-3060 [alx@macbiocom.com](mailto:alx@macbiocom.com)